Corante - pipeline.corante.com - In the Pipeline
General Information:
Latest News:
Promise That Didn't Pan Out 27 Aug 2013 | 07:27 pm
Luke Timmerman has a good piece on a drug (Bexxar) that looked useful, had a lot of time, effort, and money spent on it, but still never made any real headway. GSK has announced that they're ceasing p...
Not Sent Out For Review 27 Aug 2013 | 04:46 pm
Blogger Pete over at Fragment-Based Drug Discovery has a tale to tell about trying to get a paper published. He sent in a manuscript on alkane/water partition coefficients to the Journal of Chemical I...
On Conspiratorial Thinking 26 Aug 2013 | 07:38 pm
I recently had a e-mail exchange with someone who wanted me to read one of the many books out there that claims that some particular food additive is poisoning everyone. I'm not linking to the stuff, ...
Amgen Buys Onyx 26 Aug 2013 | 04:24 pm
So Amgen's bid for Onyx look like it's going through, and the reaction of John Carroll at FiercePharma was to tweet "Expect big layoffs soon". He took some flak for being such a downer, but he's right...
Options And Suchlike 23 Aug 2013 | 10:31 pm
And after that mention of CEO pay, this sounds like a good time to link to this article from Nature Biotechnology. If you've ever been curious about why different companies pay out in stock options an...
What's a CEO Worth? 23 Aug 2013 | 09:57 pm
In the case of Microsoft's Steve Ballmer, the stock market appears to be saying "About minus 18 billion dollars". As Alex Tabarrok notes here, that sort of puts average CEO compensation in perspective...
Chemistry On The End of DNA 23 Aug 2013 | 04:28 pm
We chemists have always looked at the chemical machinery of living systems with a sense of awe. A billion years of ruthless pruning (work, or die) have left us with some bizarrely efficient molecular ...
Too Many Metrics 22 Aug 2013 | 05:37 pm
Here's a new paper from Michael Shultz of Novartis, who is trying to cut through the mass of metrics for new compounds. I cannot resist quoting his opening paragraph, but I do not have a spare two hou...
A Call For Merck to Cut R&D 21 Aug 2013 | 05:01 pm
This is just what people working in R&D at Merck don't want to see. According to FiercePharma, a prominent analyst is urging the company to get its finances in line with its competitors. . .by cutting...
GPCRs As Drug Targets: Nowhere Near Played Out 20 Aug 2013 | 08:37 pm
Here's a paper that asks whether GPCRs are still a source of new targets. As you might guess, the answer is "Yes, indeed". (Here's a background post on this area from a few years ago, and here's my mo...
